Rise Nano Optics Uplists to OTCQB Venture Market and Achieves DTC Eligibility, Expanding Access to U.S. Investors

Commenced Trading on the OTCQB Under the Symbol “RNOLF” While Continuing to Trade on the CSE Under the Symbol “EYE”

Vancouver, British Columbia–(Newsfile Corp. – August 4, 2026) – Rise Nano Optics Ltd. (CSE: EYE) (OTCQB: RNOLF) (“Rise” or the “Company“)  a health technology company advancing vision care through patented nanotechnology lens solutions, today announced that its common shares have been approved to commence trading on the OTCQB Venture Market, operated by OTC Markets Group Inc. The Company’s common shares are also now DTC eligible, enhancing the accessibility and efficiency of trading for U.S. investors.

Rise’s common shares trade on the OTCQB Venture Market under the symbol “RNOLF” while continuing to trade on the Canadian Securities Exchange under the symbol “EYE”.

The OTCQB Venture Market is recognized by the U.S. Securities and Exchange Commission as an established public market and is designed for entrepreneurial and growth-stage companies committed to providing high-quality disclosure and transparency. The Company’s OTCQB uplisting, combined with DTC eligibility, is intended to broaden Rise’s visibility and improve trading accessibility among U.S. retail investors, institutional investors, family offices and investment advisors.

DTC eligibility enables electronic clearing and settlement of the Company’s common shares through the Depository Trust Company, reducing costs and accelerating the clearing and settlement process for U.S. broker-dealers and investors.

Erik Ritchie, Chief Commercial Officer of Rise Nano Optics, commented, “Expanding access to the U.S. capital markets is an important next step for Rise as we continue to build out our ECP and optical lab partnerships across North America. OTCQB trading and DTC eligibility make it easier for U.S. investors to participate in Rise’s growth as we scale SpectraGuard adoption in the United States.”

The OTCQB uplisting represents another step in Rise’s broader capital markets strategy as the Company continues to advance its ECP and optical lab partnerships in the United States, strengthen trading liquidity and increase investor awareness in the U.S. market.

About Rise

Rise is a health technology company specializing in advanced nanotechnology lens solutions designed to selectively filter high-energy visible light wavelengths. Its patented SpectraGuard technology integrates nanomaterial innovation, ophthalmic research, and scalable optical engineering to serve both clinical and consumer eyewear markets globally.

For more information, visit: www.risenanooptics.com

The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “1933 Act”) or any state securities laws and may not be offered or sold within the United States (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration requirements is available. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state of the United States in which such offer, solicitation or sale would be unlawful.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward‐Looking Statements

This news release contains forward-looking statements relating to the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the trading of the Common Shares and the future plans and objectives of the Company, are forward looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations are risks detailed from time to time in the filings made by the Company with securities regulations.

Readers are cautioned that forward-looking information is not based on historical facts but instead reflect the Company’s management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: the Company’s ability to maintain its OTCQB listing and DTC eligibility, the demand for the Company’s products and technology, including SPECTRAGUARD™, the expansion of the Company’s business partnerships and the success of the Company’s patents and intellectual property, whether future or current. This forward-looking information may be affected by risks and uncertainties in the business of the Company and market conditions.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/307696